Shannon Schultz (Sidie)
About Shannon Schultz (Sidie)
Shannon Schultz (Sidie) serves as the VP and Associate General Counsel at Day One Biopharmaceuticals, bringing extensive experience in compliance and legal roles across various pharmaceutical companies.
Current Role at Day One Biopharmaceuticals
Shannon Schultz currently serves as the Vice President and Associate General Counsel at Day One Biopharmaceuticals. She has held this position since 2023. In this role, she is responsible for overseeing legal matters and providing guidance on compliance issues within the organization.
Previous Experience at Sunovion Pharmaceuticals
Shannon Schultz has extensive experience at Sunovion Pharmaceuticals, where she worked in various legal and compliance roles from 2014 to 2023. Her positions included Associate Director of Compliance & Ethics, Director of Compliance & Ethics, and Senior Counsel focusing on Privacy, R&D, and Commercial. Her tenure at Sunovion spanned a total of four years, during which she contributed to the company's compliance framework.
Legal Career Background
Shannon Schultz has a diverse legal background, having worked at several law firms and companies. She was an Associate at Holland & Knight LLP from 2004 to 2007 and later worked at Nixon Peabody LLP as an Associate from 2007 to 2011. Additionally, she served as a Compliance Consultant and Associate Director at Aegerion Pharmaceuticals in 2014 and worked as a Legal/Compliance Contractor at AMAG Pharmaceuticals from 2013 to 2014.
Education and Academic Achievements
Shannon Schultz earned her Bachelor of Arts degree in Physics from the College of the Holy Cross. She furthered her education at Suffolk University Law School, where she graduated magna cum laude with a Juris Doctor degree. Her academic achievements reflect a strong foundation in both science and law.
Professional Development and Leadership Roles
Throughout her career, Shannon Schultz has taken on leadership roles in compliance and legal functions. She served as Team Lead at Counsel On Call in 2011 and 2012. Her progression through various compliance and legal positions demonstrates her commitment to professional development and expertise in the pharmaceutical industry.